Good morning, Welcome to the IDEXX Laboratories Q1 2023 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Brian McKeon, Chief Financial Officer; and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the investor relations section of our website, idexx.com. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is provided in our earnings release, which may also be found by visiting the investor relations section of our website. In reviewing our Q1 2023 results, please note all references to growth, organic growth, and comparable growth refer to growth compared to the equivalent period in 2022, unless otherwise noted. To allow broad participation in the Q&A, we ask that each participant limits their questions to one with one follow-up, if necessary. We appreciate you may have additional questions, so please feel free to get back into the queue, and if time permits, we'll take your additional questions. Today's prepared remarks will be posted to the investor relations section of idexx.com after the earnings call concludes. I would now like to turn the call over to Brian McKeon. Good morning, welcome to our Q1 earnings call. IDEXX had a solid start to 2023. In terms of highlights for the quarter, overall revenues increased 10% organically, supported by nearly 12% organic growth in CAG Diagnostic recurring revenues. CAG Diagnostic recurring revenue gains were driven by nearly 14% organic growth in the U.S., supported by solid volume gains and benefits from a higher net price realization. Key execution metrics remained strong globally, reflected in record Q1 premium instrument placements, continued solid new business gains, and sustained high growth in recurring veterinary software revenues. Operating profits and EPS increased 18% on a comparable basis, reflecting solid organic revenue growth, better than expected gross margin gains, and benefits from a $16 million customer contract resolution payment. These strong results reflect the durability and resiliency of the IDEXX business model and benefits from our ongoing focus on execution. We've incorporated our Q1 results and positive adjustments to our full year financial outlook, which we'll discuss later in my comments. Let's begin with a review of our Q1 results. Q1 organic revenue growth of 10% was driven by 11% CAG gains and solid 8% growth in water. Overall, organic revenue gains were moderated by 2% declines in our LPD business and approximately $4 million of revenue headwind related to lower human COVID testing revenues, a business area that we winded down completely in Q1. CAG Diagnostic recurring revenue increased 12% organically, reflecting 14% gains in the U.S. and 8% growth in international regions. CAG Diagnostics recurring revenue growth was supported by global net price gains in the 8%-9% range, consistent with our expectations. Overall organic revenue gains were also supported by 14% organic growth in veterinary software and diagnostic imaging revenues. CAG instrument revenues were down 7% organically, reflecting comparisons to high prior year levels, program pricing effects, and global mix. IDEXX CAG Diagnostics recurring revenue growth remains solidly above sector growth levels. In the U.S., we achieved a 1,350 basis point growth premium compared to relatively flat same store US clinical visit growth levels in Q1. These results reflected benefits from execution drivers, including higher net price realization. Solid US volume growth was supported by new business gains, high customer retention levels, and continued increases in diagnostic frequency and utilization at the practice level. International CAG Diagnostics recurring revenue gains were also supported by strong IDEXX execution, reflected in higher net price realization, sustained new business gains, and a double-digit expansion of our premium instrument install base. Double-digit growth rate benefits from these drivers were moderated by impacts from challenging international macro conditions, which continued to pressure same store volume growth trends in the quarter. Globally, IDEXX achieved strong organic revenue growth across our modalities in Q1. IDEXX VetLab consumable revenues increased 12% organically, with double-digit gains in the U.S. and international regions. Consumable gains were supported by 11% year-on-year growth in our global premium instrument install base, reflecting double-digit increases across our Catalyst premium hematology and SediVue platforms. We placed 4,425 CAG premium instruments in Q1, an increase of 3% year-over-year compared to very strong prior year levels, building on the record placement levels achieved in the Q4 of 2022. The quality of instrument placements continues to be excellent, reflected in 7% growth in new and competitive Catalyst placements. ProCyte One momentum also continues to be strong globally, reflected in a global install base that more than doubled over the last year to 9,400 units. Global rapid assay revenues expanded 12% organically, driven by strong growth in the U.S., reflecting solid volume gains and benefits from higher net price realization. Global lab revenues increased 11% organically, reflecting strong gains in the U.S. and mid-single-digit growth in international, with growth in key international regions moderated by macroeconomic impacts, which have pressured same-store sales. In terms of other areas of our CAG business, veterinary software and diagnostic imaging revenues increased 14% organically. Results were supported by continued high levels of organic growth in recurring software and digital imaging revenues and ongoing momentum in cloud-based software placements. Water revenues increased 8% organically in Q1, reflecting solid gains in the U.S., Europe, and Latin America, including benefits from net price improvement. The integration and performance of our recent TECTA-PDS acquisition has progressed well, expanding our capabilities in water safety testing. Livestock, poultry, and dairy revenue decreased 2% organically as solid gains in the U.S. and Europe were offset by comparisons to high prior year sales levels in herd health screening and reduced revenues from non-core food and safety products in certain regions. Turning to the P&L, Q1 profit results were supported by a 150 basis points improvement in reported operating margins, reflecting 10% organic revenue growth, solid gross profit gains, and benefits from a $16 million customer contract resolution payment. Gross profit increased 9% in the quarter as reported, and 12% on a comparable basis. Gross margins were 60.3% up 120 basis points on a comparable basis. Benefits from higher net price realization, lab productivity initiatives, improvement in software service gross margins, and business mix offset inflationary cost effects. Later timing of lab staffing increases and select operational upsides also supported Q1 gross profit results. As expected, reported gross margin gains were moderated by a 50 basis points negative impact related to foreign exchange changes, including lapping of prior year hedge gains. Operating expenses increased 5% year-over-year as reported in the quarter, and 7% on a comparable basis. This was net of a $16 million or 6% operating expense growth offset related to the customer contract resolution payment. As planned, we saw higher growth in sales and marketing and R&D expense in the quarter related to specific factors, including the return of in-person sales meetings this year and advancement of key innovation initiatives. EPS was $2.55 per share in Q1, an increase of 12% as reported and 18% on a comparable basis. Foreign exchange reduced operating profits by $12 million and EPS by $0.11 per share in the quarter, including impacts from the lapping of prior year hedge gains. Free cash flow was $144 million in the Q1. On a trailing 12-month basis, our net income to free cash flow conversion ratio was 65%. For the full year, we're maintaining our outlook for free cash flow conversion of 80%-90%, including estimated capital spending of $180 million. Our balance sheet remains in a strong position. We ended the quarter with leverage ratios of 1.1x gross and 1 time net of cash, down modestly from Q4 levels. Share repurchases over the last year supported a 1.9% reduction in diluted shares outstanding. We did not allocate capital to share repurchases in the Q1 as we manage our balance sheet relatively more conservatively in the current interest rate environment. Turning to our 2023 P&L outlook, we're refining our full-year outlook to incorporate our solid Q1 operating results and updated estimates for foreign exchange impacts. We're updating our full-year guidance for reported revenues to $3.615 billion-$3.7 billion. This includes a $10 million positive adjustment for foreign exchange impacts, which we now estimate will provide a relatively modest full-year headwind to reported revenue growth. Our updated outlook for overall organic revenue growth is 7.5%-10%. Our Q1 results track towards the high end of this range, and we're maintaining consistent high-end targets for our performance this year, reflecting benefits from execution drivers and the potential for reduced clinical visit growth headwinds. As part of our financial management approach, we incorporated risk estimates to our targeted growth performance in the low end of our organic revenue growth range, including potential effects from macroeconomic conditions. We raised the low end of our full-year organic revenue growth outlook by 0.5% in our updated guidance, incorporating our solid start to the year. We're maintaining our outlook for solid operating margin performance in 2023, with an expectation for reported operating margins in the range of 29%-29.5% for the full year. At the high end, this reflects an outlook for approximately 340 basis points in comparable operating margin expansion. This includes approximately 280 basis points in combined benefit from the $16 million Q1 customer contract resolution payment and the lapping of $80 million of discrete R&D investment in the Q2 of 2022. We now estimate that foreign exchange will reduce reported operating margins by approximately 60 basis points this year, slightly higher than earlier projections, which included impacts from the lapping of $26 million in 2022 hedge gains. Our updated EPS outlook is $9.33-$9.75 per share, reflecting a $0.06 per share increase in our low-end estimate. We continue to estimate that foreign exchange impacts will decrease EPS by approximately $0.23 per share for the full year, with the bulk of this impact in the first half. In terms of our operational outlook for Q2, we're planning for overall organic revenue growth consistent with the midpoint to higher end of our full-year growth outlook range, with approximately 1% of reported growth headwind from year-on-year FX changes. In terms of Q2 operating margins, we're planning for reported operating margins in the range of 29%-29.5%. This reflects expectations for relatively consistent operating margin performance year-on-year, adjusting for about 70 basis points in negative foreign exchange impacts and benefits from comparisons to prior results, which included $80 million in discrete R&D investment. We provided details on our updated outlook in the press release tables and earnings snapshot. We're applying a disciplined financial approach that advances our growth strategy and mitigates potential macro risks to ensure delivery of continued strong financial performance. That concludes our financial review. I'll now turn the call over to Jay for his comments. Thank you, Brian. Good morning. I'm pleased to share that IDEXX had a very strong start to 2023, driven by sustained execution of our growth strategy. Demand for companion animal medical services continues to grow, supported by IDEXX innovation and direct customer engagement. Veterinarians continue to focus on meeting these high levels of demand with the best possible medical care, with diagnostics as an essential component of this care equation. IDEXX remains a chosen, trusted partner to veterinarians who appreciate how our world-class products and connected ecosystem enable high standards of care while resulting in growth of a significant profit center within their clinics. IDEXX's strong execution is reflected in double-digit total company organic revenue growth, supported by strong expansion of global CAG Diagnostics recurring revenues. Growth in this recurring revenue annuity was supported by solid contribution for new business gains, sustained high customer retention rates, and net price realization aligned with our expectations. Our commercial teams drove another record quarter for global premium instrument placements and excellent levels of cloud-based software placements. IDEXX products and services offer solutions to improve clinic productivity and support the significantly expanded and underserved demand we've seen for pet healthcare in recent years, including net pet additions in the U.S. of 2% in 2022, twice the pre-pandemic trend line. These efforts supported strong IDEXX growth as we continue to work effectively through the near-term sector headwinds related to clinic capacity constraints and global macro conditions. Today, I'll discuss how IDEXX's sustained execution against our strategy to drive the adoption and utilization of diagnostics help deliver continued strong financial results. First, I'll provide an update on our commercial execution, which through education and customer engagement, drives relevant utilization of IDEXX's innovative solutions. IDEXX commercial teams delivered another record Q1 global premium instrument placements to start 2023, building on very strong prior year results. Our commercial teams demonstrated a continued ability to advance placement, quantity, and quality. This is reflected in strong growth in Catalyst placements in new and competitive accounts globally, driving solid EDI achievement. These commercial results are highly encouraging as we address a significant opportunity for an estimated 220,000 worldwide premium instrument placements and give us confidence that we have the right strategic playbook in place. IDEXX professionals provide world-class software-enabled products that are in high demand and supported by a wide menu of customer-friendly marketing programs that enable adoption of new technology. These results also reflect continued strong clinical interest in using IDEXX's products and services to not only meet the increased demand for pet healthcare, but to deliver the best possible level of care. Our commercial execution is supported by the multiplier benefits that flow from IDEXX innovations, as evidenced by the success of our newest hematology analyzer, ProCyte One. ProCyte One provides customers with an attractive in-clinic hematology solution. Its small footprint, easy pay-per-run model, and lower cost come without sacrificing CBC performance. IDEXX premium placements have benefited from strong ProCyte One adoption to date, thanks to sustained high attach rates with Catalyst, as defined by ProCyte One placements either with a Catalyst or at an existing Catalyst customer. The result is a multiplier benefit, supported by clinics who choose to outfit their in-clinic suite with IDEXX products. As a result, we are nearly halfway to the incremental 20,000 premium hematology placement objective we shared at Investor Day following ProCyte One's launch, while the strong attach rate should also help IDEXX penetrate the long-term worldwide placement opportunity. Key to developing this long-term opportunity will be increasing customer engagement in international regions. We're leveraging our successful BDC model to build strong relationships with international customers, as evidenced by sustained strong new business gains and a 19% increase in Catalyst placements. This strong performance is allowing us to deliver solid CAG Diagnostics recurring revenue growth in international regions, despite continued macro headwinds which have pressured same-store clinic visit levels. Customer engagement remains excellent, as evidenced by high reach to revenue levels in the Q1, including benefits from our expanded commercial sales force in targeted regions. The flywheel is beginning to turn in these countries, where we've seen excellent gains from new business, strong interest in engaging with customer marketing programs, and solid overall volume growth. Commercial expansion is an important early step in our international strategy, supporting recent efforts to optimize our reference lab network, roll out highly relevant products like ProCyte One, and drive further adoption of software tools like VetConnect PLUS, our cloud-based diagnostics portal. Software innovation continues to be a key driver of our growth strategy globally. IDEXX software solutions are a key enabler of diagnostics utilization. Creating a connected ecosystem that helps improve diagnostics workflow while providing deeper clinical insights and supporting pet owner communication. It's an attractive standalone business as well. Strong PIMS placements in the Q1 were supported by continued preference for cloud-native products, with IDEXX well positioned to address this trend. Placements of cloud-based products maintained the strong velocity we saw coming out of 2022 and represented greater than 90% of total placements, supported by continued high interest in our EasyVet and Neo solutions, which are seamlessly integrated into our product offering. This provides customers with options when it comes to picking the best, most relevant PIMS solution for their clinic size and workflow complexity. Our strong Q1 placement performance supported double-digit recurring revenue growth with an attractive gross margin profile, and we're on track to achieve this year a PIMS footprint that is over 50% cloud-based. This milestone is especially important in the current veterinary clinic environment, where productivity is a priority in addressing the sustained high levels of demand since the pandemic. By embracing IDEXX's cloud-based ecosystem, customers gain the advantage of an easy-to-use software stack that touches every area of the veterinary clinic. The benefit of these tools is enduring for our customers, evidenced by strong engagement metrics across applications, including increasing rates of our IDEXX Web PACS user base that are power users, as well as sustained rates of VetConnect PLUS users who use the software as part of their daily routine. Adoption and continued use of these products allows veterinarians and their staff to spend more time focused on the care they deliver to their patients rather than on costly, time-intensive administrative activities. Our software strategy is to increase cloud adoption and build increased business and clinical functionality into IDEXX software solutions. Another use case of our innovation agenda is our 4Dx Plus test, the gold standard test for canine vector-borne disease testing. The current 4Dx Plus test is our fourth version of a multiplexed canine vector-borne disease diagnostics over the past 20+ years, with improved sensitivity in Anaplasma and 2x increase in the ability to store the product at room temperature. This is a true testament to our Technology for Life strategy and supported 12% global organic rapid assay recurring revenue growth and solid customer gains in the Q1. A full vector-borne screen using 4Dx Plus is recommended over a heartworm-only test given significant increases in incidence and prevalence of vector-borne diseases over the past 10+ years. Yet, in 2022, less than one in every five dogs received this comprehensive level of testing. 4Dx Plus enables veterinarians to deliver this higher standard of care with follow-up testing and care protocol guidance provided through DecisionIQ, which aim to drive better health outcomes while encouraging increased diagnostics testing. Furthermore, our entire rapid assay franchise is supported by the SNAP Pro Analyzer. The analyzer not only simplifies the workflow when running a SNAP test, but also ensure the diagnostic results flow seamlessly to VetConnect PLUS and ultimately result in charge capture and invoicing at the point of sale. This is a clear case of how our products, integral components of our connected software ecosystem, improve in value over time while delivering a multiplier benefit to our customers and drive IDEXX CAG Diagnostics recurring revenue. The sustained execution against our commercial and innovation agendas is made possible by an unrelenting focus on our customers and ensuring they have world-class experience with IDEXX. This takes multiple forms, all focused to ensure our customers have the resources they need to provide the best possible levels of medical care. Continued 99% plus product availability and reliable, fast reference lab service turnaround times provide them with important business continuity and are the result of our investment in manufacturing and supply chain logistics teams, facilities, and relationships. Additionally, the support of the high-touch, highly knowledgeable sales teams that we have built out over the decades ensures they have the products and services that are right for their busy clinics. Our customers realize the benefits of the IDEXX partnership every day, and in turn reward us with their business and their enduring loyalty as measured by another quarter of consistent high customer retention rates. Providing our customers with reliable, consistent support is even more essential right now given the dynamic backdrop of our sector. High demand for animal medical services combined with sustained labor supply constraints continue to create productivity and growth challenges at the clinic level. Taking our customer support efforts a step further, we recently published an empirically based study which examines the drivers of productivity within a practice and helps customers to understand their productivity strengths and areas for opportunities. Through this rigorous effort, we found three key drivers of practice productivity. Number one, workflow, which includes staffing models like optimized technician-to-veterinarian mix and staff and patient-friendly physical layout of the practice. Number two, technology, or digitizing each step of the patient workflow to remove high-effort administrative routines. Number three, the role of culture, including clarity of roles and responsibilities, investments in training and staff effectiveness, and aligned incentives to drive teamwork and achievement of practice goals. As a result of this initiative, we believe there's still great opportunity for clinics to improve productivity measures. We look forward to educating and supporting our customers in these efforts. Opportunities to do so could result in 30% or more incremental visit capacity, even for practices that are in the top cohort of productivity. We are integrating elements of these efforts into our strategy and commercial approach this year. With that, I'll now conclude the prepared remarks portion of the call by thanking our nearly 11,000 IDEXX colleagues for the commitment and passion they bring to our purpose-driven work every day. Your efforts not only help provide a better future for animals, people, and our planet, but you also supported IDEXX in starting 2023 on a strong financial note. We have an attractive sector and a strong track record. The opportunity ahead of us, which is significant, is to work with our customers to elevate companion animal healthcare standards to increase diagnostics utilization. The tireless work of the IDEXX team has positioned us well to deliver solid growth and financial results into the future. On behalf of the management team, thank you for your continued focus on enhancing the health and well-being of pets, people, and livestock. Let's open the line for Q&A. If you'd like to ask a question, please signal by pressing star one on your telephone keypad. If you are using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. A voice prompt on the phone will indicate when your line is open. Please state your name before asking your question. Again, that's star one to ask a question. We'll take our first question from Nathan Rich. Thanks for the question. Hi, Nate. Hi. Hi, good morning. Thanks for the questions. Had two on the updated guidance. You know, Brian, on top line, I think you've talked about targeting the high end of the CAG DX recurring revenue range at 11%. You know, Q1 came in a bit better than expected. I guess, any change in how you're thinking about getting to that for the full year, you know, and any change in assumptions on either kind of the U.S. or international outlooks, based on what you've seen through the Q1? Thanks for your question. We have a similar outlook at the high end. I think we feel very good about the start to the year, particularly in the U.S. I think the drivers of that, we highlighted pricing being a positive driver for us this year, and the execution is consistent with what we had expected. I think the executional drivers that help to deliver solid volume growth in the U.S. we're very encouraged by and looking to build on that. I think internationally, we also saw excellent execution drivers. I mentioned we had double-digit growth benefit from things like new business gains, including benefits from strong instrument placements, higher pricing. We are seeing continued headwinds from macro factors in international markets, the growth was somewhat below our higher end targets. On balance, we feel a good start to the year. Still think that's a good full year goal for the company and looking forward to continuing to execute well to deliver against it. Okay. I wanted to also follow up on the operating margin guidance. I think you mentioned kind of unchanged outside of the FX impact. Gross margin, I think you said, came in better than expected, but was offset, I guess, by higher OpEx. Could you maybe just talk about how that plays out over the balance of the year? You know, especially sales and marketing, I think, was up meaningfully as a% of revenue in the Q1. Just what drove that increase, and how should we think about the run rate for the full year? Yeah, let me try to break that down. We had an expectation for the Q1 for an improvement in reported operating margins of 50- 100 basis points. We came in at 150, so that was better than expected. That was principally on the gross margin line. We saw some benefit in the quarter from kind of later than timed planned staffing in areas like our labs and some specific operational factors, more Q1 related. I think we feel good about the overall performance and, you know, do think that the high-end goals that we have are still appropriate. As we highlighted coming into the year, we knew that we had some costs coming back here, just more interface with our customers, more travel. I think we're anticipating that to continue. We're trying to support our employees in a higher inflation environment as well. We do have investments that we're advancing in areas like R&D. I know we've highlighted in the past the, you know, couple new platforms that we're advancing, that we're investing behind. Those are all captured in our outlook. I think on balance, our performance is very much in line with what we were targeting. Again, good start to the year, and we think we. You know, the full-year goal is on a, if we adjust out the R&D lapping and the customer contract resolution payment are for a solid 60 basis point comparable improvement, you know, right in line with what we were hoping to achieve this year, and we look forward to work and deliver on that. Great. Thank you. Our next question comes from Chris Schott from JP Morgan. Great. Thanks very much. Just two questions from me. The first was just any comments on the Mars Heska proposed acquisition and the impact that could have on the competitive landscape? My second one was just a question on price. Just turning my hands around just feedback you're getting on the moves you've made. Are you seeing any impact at all on demand from these changes as we think about whether it's wellness visits or less acute conditions? I know that's kind of seems to be kind of topic that's top of mind for investors. Just love to have any, you know, just, you know, directional comments of what you're hearing on price would be appreciated. Thank you. Yeah. Good morning, Chris. This is Jay. Let me take your second question first, I'll address. The acquisition. You know, overall, we think pricing to our customers is appropriate within the current environment. You know, from an overall demand standpoint, we see that holding up well, you know, relative to the macro conditions as we've described it in the different pricing scenarios. From just a, you know, pet owner perspective, we think, you know, they demonstrated a willingness. We see this both from experience as well as just the survey work that they continue to prioritize, you know, healthcare for their pets. Keep in mind that diagnostics is a relatively small piece of the overall, you know, patient spend on their pets. You know, specifically to your point around wellness versus non-wellness, you know, we've seen the two pretty much move in lockstep over the last, you know, five quarters, you know, or so. You know, of course, if the, you know, macro when we've seen sort of the macro deterioration from an environmental standpoint during the pandemic, there was some divergence. But, you know, generally, at least over the last year plus, they've moved in lockstep. And, you know, just an interesting, I think, proof point to that is you take a look at the 4Dx diagnostics, you know, testing. It's been highly durable. That's primarily a, you know, a wellness test and we think indicative of the, you know, good end customer demand and pull-through. From the standpoint of the Mars Heska acquisition, just as a matter of policy, we don't comment on specific, you know, customer relationships except to say that, you know, no single customer comprises more than 10% of our consolidated revenues. Our customer base is very large and diversified, I think, as you know, and we maintain and have excellent relationships and a great long-term track record with our corporate customers. They, I think, very much appreciate the broad solution portfolio, both on the diagnostics as well as software side, where we can support their objectives to grow and deliver great care. Probably just as importantly, footprint-wise, to be where they are. You know, I think the acquisition itself reflects, you know, what we've said all along, the attractiveness of the animal health sector and more specifically, diagnostics that we think, you know, long term, that it can help support the overall market or sector development of diagnostics. Thank you. Again, if you would like to ask a question, it's a signal by pressing star one on your telephone keypad. We'll take our next question from Jonathan Block from Stifel. Yeah, hi, it's Jon from Stifel. Can you guys hear me okay? Yeah, we can. We got you, Jon. Sorry. The operator jumped in, I guess as they were teeing me up. Sorry about that. First question, Brian, you know, it was a good quarter. The CAG DX revenue of $11.6 was above the high end of your prior, $8.5-$11. I think you expected on the, on the last call, one to 23 to be more at the midpoint of the annual guide, and you came in above the high end. Maybe just talk to us on what drove the upside. I believe price was in line with your prior thoughts. You know, do you chalk it up more to U.S. than international? That would be my knee-jerk reaction, but would love to hear from you. If it is in the U.S., is it more specific to, call it, IDEXX drivers, or did you see, you know, some upside, call it to industry visits relative to where your head was at three months ago? Thanks for the question, Jon. We did have a really good start to the year in the U.S. I think our pricing, as you pointed out, was globally in line with what we had planned, so we feel good about the execution there. I would say the U.S. clinical visits were overall for the quarter, a little better than we anticipated. They were flat, as you mentioned, and we thought we'd still be working through some compares on that front. I think, you know, the got some benefit really early in the quarter, I think, with some positive growth that helped there. Our own volume execution, you know, the difference between, you know, how much growth is coming from our volume relative to clinical visits was a solid 5%. That's kind of pre-pandemic levels. That was in line with kinda where we're hoping to achieve. On balance, U.S. combined came through quite well. I think international was in line, I would say, with what we were guiding towards. We had very good execution as noted and continued to see some macro headwinds that we're working through. On balance, I think we feel good about the start to the year as I shared earlier. You know, we have some goals at the higher end that would help us deliver 10% overall organic growth, which is our goal, and we think we're working well towards that. We acknowledging that we're in an environment where there is some macro risk, and we think it's prudent to have a range of estimates there and continue to monitor those trends as we work through the year. I think on balance, feel good about the start. Yeah. I would just build on that to state that I would build on Brian's comments and just emphasize the excellent commercial drivers that we've talked about. Certainly pricing, as Brian mentioned. You know, new customer acquisition has been strong, both U.S. and internationally. Customer retention rates, you know, continue to remain strong. I think, you know, the customer interest and appetite for technology, we see that in premium instrument placements as well as software. I think that's really reflective of the, you know, some of the capacity challenges that they see. Overall, I think from an execution standpoint, very strong quarter. Perfect. That was helpful, guys. Thanks for that. Next one might have a couple parts to it. Brian, just below the line for the guide, is it essentially a wash? Like there's some less interest expense, but there's less share repo. You had some wording around the hedges and the way that flows through the change. Just broadly speaking, below the line, is it a wash when we think about your current 23 EPS versus where it was back in February? The second part of that question is, guys, even if you keep it at a high level, can you just talk about what needs to be done for the 2 new point of care systems? Are those initiatives running in parallel, just when we think about timing there? Thanks for your help. Just to clarify on the profit guide, our operating margin outlook is consistent. We have a slightly higher headwind from FX, on a comparable basis, the high end's the same and the low end's up, I think, slightly. We obviously have some positive flow-through from raising the low end in the revenue, you know, that's the EPS adjustment. You're correct, we had lower interest expense projected offset by relatively lower projected reductions in shares outstanding, that was a net flat effect. I would just say from a product development standpoint, you know, I'm not gonna be specific obviously, but, you know, we are running parallel programs. We continue to invest in software, assays, instruments. We spend a lot of money on innovation. We think there's great opportunities across the portfolio, and we'll continue to provide updates as we get closer. Thank you. Our next question comes from Michael Ryskin from Bank of America. Great. Thanks for taking the question, guys. Jay, Brian, I wanna start on OUS specifically. Could you just clarify, I think you said 8% OUS, was that CAG recurring or CAG total? Then just in general, did that come in line with expectations? Anything specific you can call out on OUS results? I know you just commented on, you know, the macro environment, but anything more than you can point to either by region or by sort of the factors that are driving that? Yeah. Let me clarify the numbers. I'll let Jay talk to the regional dynamics. It was 8%, 7.6% CAG ex recurring. Mike, I would say that's pretty much in line with the outlook that we shared for the quarter. I think the execution drivers were strong in line. We had 17% growth in instrument placements, double-digit benefit from, you know, things that weren't related to same store sales dynamics. We continue to see the, you know, kind of pressure that we've seen from macro trends on the same store side. We've been building that into our outlook, and I think that was, that was in line with what we were anticipating and kind of consistent with our full-year view as well. Yeah. I mean, just to support that, we've seen, you know, relatively speaking, more macro impacts outside the U.S. As I had mentioned, you know, previously, our execution drivers internationally have been excellent. We've done seven commercial expansions. When you take a look at those targeted expansions, you know, we're doing well. You know, we're bringing more focus and from a frequency and in-visit standpoint, the type of successful model that we've implemented in the U.S. From a, you know, an instrument and business focus standpoint, we've seen excellent results in premium instrument placements. I think 19% on the Catalyst side, really strong. The quality has been really strong from both competitive and new placements. We're optimistic, and I think the, you know, the regions are working or the countries within the regions are working through, you know, their specific challenges. You know, we're optimistic that the long-term demand is there. Okay, great. Thanks. For the follow-up, going back to the organic growth guide for the year and sort of your assumptions on vet visit growth, I think previously you'd said that, you know, on the high end of the guide, you're baking in a relative flattening of clinical vet visit growth trends as you work through the year. As you said, you kind of saw them in the Q1 already. What do you need to see from vet visits or the clinic trends to say, "Okay, you know, we're here already, things have definitely improved. We're ready to revise that upward." Is that just a matter of seeing these trends continue for another quarter or so, or is there something that you saw in between the numbers that gave you pause? Maybe I can provide a little color there, on the US side where, you know, we're more explicit on how we're thinking about the visit trends. As I mentioned, the overall, it was clinical visits were relatively flat in the quarter. I think we are encouraged that it appears that we're working through the headwinds that were related to capacity staffing, so that seems to be normalizing. I would point out it was stronger earlier in Q1 than how we exited the quarter. The visits were down a bit in March, and that continued into early April. I think this is an ongoing dynamic in terms of just the macro backdrop and the ongoing adaptation of clinics to adding staffing, kind of getting back to their normal growth rates. I think We're feeling good about kind of working through some of those headwinds that we highlighted and, you know, an area that we'll continue to monitor and we're actively trying to help, clinics, through productivity improvement, get back to the positive growth rates that they've been able to support in the past. Yeah. You know, to Brian's point, the practices from our perspective, speaking now to the U.S., have largely stabilized. We've seen stabilization of ours, for example. I think there's been, you know, really strong appetite and enthusiasm for technology, you know, specifically with a focus on productivity and supporting capacity. Certainly, we've seen, you know, heightened interest in software as a way of supporting staff productivity, workflow optimization, you know, removing the sort of high administrative unrewarded, you know, tasks. Keep in mind, if you take a look at 2022, there was a 2% net addition in pets in the U.S. That's twice the level pre-pandemic. I think there's a lot of underserved demand, you know, out there, and practices are working through, you know, how they, how they serve that demand. Good progress. I think the, you know, the other thing is finding the time study, we think identifies some things that practices are doing and could do, and there's been a lot of receptivity and enthusiasm for that work and how they can find, you know, a couple minutes here, a couple minutes there that cumulatively make a big difference. Got it. Really helpful. Thanks, guys. We'll take our next question from Ryan Daniels from William Blair. Yeah. Hey, guys. This is Jack Senft for Ryan Daniels. Thanks for taking my question. I have two just pretty quick ones. First, can you remind us on the ProCyte One placement goals or placements goal? I believe the 20,000 goal is for 2026, correct? I believe in your prepared remarks, you said that you're already over 50% to that target. Just curious if you can touch on the good performance in these placements that seems to be almost ahead of schedule. Two, do you expect the adoption to slow down, or is there a good amount of upside potential to that 20,000 target? Thanks. Yeah. Let me address the. We had said that we had 9,400 ProCyte One placements, which is nearly half of the goal itself. And I think what we're seeing is a really nice fit with the, you know, the platform itself from both a, you know, performance and cost and footprint standpoint. There's been a lot of, I think, customer adoption based on the fact that it fits their practice needs. You know, keep in mind internationally, which is where we think the larger part of the marketplace is, in many countries, it's hematology first. They do sort of a general body systems, you know, diagnostic and then in some cases include chemistry or may include chemistry, you know, with it. In those hematology first marketplace, they, you know, see this as a, you know, key addition to their in-clinic diagnostic suite. We've done well with that. Yeah. I'd just highlight the multiplier benefits too of the ProCyte One launch. If you look at the growth in the overall install base, we had double-digit growth across Catalyst, premium hematology, and SediVue. We had a very strong quarter for Catalyst and SediVue placements, you know, building on the lapping of the, of the launch last year that was very successful for ProCyte One. I think the, the, the benefit of having additions to a platform isn't just related to the platform itself, but, you know, to the overall business growth. Perfect. Understood. Thanks. Just as a quick follow-up, you know, over the past few quarters, the narrative of cloud within the animal health industry seems to have accelerated. Just given the financial hardships that practices currently face, can you just talk about the pricing differences between, you know, average cloud-based solutions versus, like, on-prem or hardware solutions? For new practices starting up, are they typically going just right into the cloud? Or I guess, like, what is the opportunity here? Thanks. New practices are generally, you know, going right into the cloud. They're, you know, they're trying to buy and use contemporary technology. You know, cloud-based systems are obviously priced as SaaS, you know, services. There's a, you know, there's a monthly annuity. There's still upfront costs in terms of data migration and onboarding and training and those things associated with getting a practice up to speed. I think the big difference from a cost standpoint at least, is in the life, you know, cycle of the solution itself, that the practices don't have to worry about replacing servers every three, four, five years and paying for ongoing, you know, maintenance. The other, you know, big benefit is they get software updates, you know, pushed to them on a pretty frequent basis without having to necessarily send somebody out to the site and, you know, take the system offline, whether it's, you know, a couple of hours or more. I think there's a lot of cost benefits over the life cycle of the solution, as well as feature functionality, you know, improvements that they get. Therefore, that's driving, I think, at least in the veterinary industry, you know, a newfound appreciation for, you know, updating to more modern or contemporary software solutions. Our next question comes from Erin Wright from Morgan Stanley. Oncology diagnostics Sorry, hopefully you can hear me now. can you talk a little bit- Hey, Erin, we missed the beginning of... Yeah, sorry. Yeah. We missed the beginning of your question. No worries, no worries. Can you talk a little bit about the pet oncology diagnostics opportunity? Why does it make sense for you to partner in this category versus buy? Do you think that this could be a more meaningful driver for you longer term or more limited? Just curious how you're thinking about that at this juncture. Thanks. Yeah, Thank you, Erin. We think it's a very significant, you know, opportunity just based on the number of pets that develop cancer. It's the biggest cause of death mortality of, you know, within the pet population. If you take a look at the U.S., there's 6 million dogs a year that get cancer. 3x mortality rate of the next sort of greatest cause of death. The diagnosis and staging and treatment protocols today are very fragmented. They tend to be late by the time it's very clinically obvious, then you have to, you know, take the sample and send it out to the pathology lab. At that point, cancer may be stage 3, stage 4, difficult to treat. The other piece is that, you know, there aren't a lot of oncology specialists. If you take a look at North America, it's 350- 400. Most of the cancer diagnosing and treatment is happening through the general practitioner who aren't specialists. They have a lot of other responsibilities. Being able to provide diagnostics as a, you know, testing regime for them, we think is a really attractive opportunity. We both partner and have internal development efforts. Keep in mind that from a cancer standpoint, just our pathology submissions on a global basis, over 1.3 million a year. This isn't a new area for us. This is something that we're well-versed in and provide a, you know, service across the globe for. This is just really expanding or enhancing so that we, you know, we move earlier into being able to support our customers that to diagnose cancer while it's still, you have better chances of being able to treat it. Great. Thanks. I know you commented a little bit on the Heska-Mars deal, do you anticipate more opportunities in terms of corporate relationships coming up outside of obviously Mars and with a couple of their relationships on the Heska side coming up for bid within the next year, is that meaningful at all? What's the competitive response? Thanks. I mean, we have. You know, generally, we have relationships with most corporate accounts, you know, across some of our different testing modalities or product lines. You know, we do think there are some customers who may be sensitive to, you know, continuing with our competitors. You know, it's, it still comes down to very competitive market. It still comes down to, you know, we're gonna have to compete customer to customer. At the end, we think that the broadest possible solution to support their growth objectives is what at the end of the day, you know, wins, and we'll continue to focus on that. Okay. Thanks. Next is our last one. Our last question. Oh, sorry, excuse me. From David Westenberg from Piper Sandler. Hi, thank you for taking the question here. Sorry if it went over my head in terms of the FX here. I think on the change in guide, it was from 500 or 50 basis points on revenue to 200 basis to 20 basis points on revenue. On EPS, it went up. Sorry, I might be a little thick-headed here. Can you explain what's happening on the top line? I think of you as an exporter, so I'm just a little bit confused there. I know you've given commentary, but maybe I'm a little slower than others. I'll just ask my second one up front here. Can you talk about again, another one on the Mars-Heska thing, but I wanna go at a different angle. you know, your win rate against Antech has been pretty high, and at least my checks from, with veterinarians tend to see that, you know, they kinda have, don't like, you know, going against their competitor. Is there any chance you can have additional win rates in the inside lab here, with kind of that angle and kinda how to think about that dynamic? Thank you very much. Yeah. David, just on your FX questions, you're correct on revenue. We think the full year is relatively flat now versus what we thought was a half point headwind. That's the $10 million positive adjustment in revenue. It didn't flow through to EPS just given mix of currencies and hedge positions. It's, you know, the, you know, we share all the assumptions relative to rates, but we have a, you know, model that we go through looking at all those factors, and it didn't have a net impact just because we're largely hedged at this point and just the mix of the impacts weren't as favorable. Yeah. To answer your second question. You know, we don't think about it necessarily as migration of one modality to the other based on the competitive landscape. You know, customers use both in-clinic as well as reference labs. You know, they choose partners based on a variety of your product and solution differentiation, you know, cost, service, footprint, you know, all those things. We think they're still gonna be, you know, the primary drivers of, you know, who corporate customers and independent customers choose, and I'll leave it at that. With that, we'll conclude the Q&A portion of the call. Thank you for your participation this morning. To summarize, I'll reiterate that IDEXX is committed to the significant multi-decade opportunity to increase the standard of care for companion animal healthcare. We look forward to executing our organic strategy to address this opportunity. IDEXX teams continue to perform at a high level, building up the investments we've made over the past decades to develop our sector. We look forward to continuing strong progress against our strategy through 2023. Now we'll conclude the call. Thank you. This concludes today's call. Thank you for your participation. You may now disconnect.